Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 55 No. 4
PSYCHOPHARMACOLOGY BULLETIN

VOL 55 No. 4

Articles in This Issue

ORIGINAL RESEARCH

Pilot Trial of SDX/d-MPH Adult ADHD Examining Effects Throughout the Day

Lenard A Adler, Dayeon Cho, Terry Leon, Mariane Guschwan, Caleb A Massimi, Deepti Anbarasan
Objective To examine the effects of Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) on ADHD symptoms throughout the day in adults with DSM-5 ADHD. Method This was a 6-week pilot study that included 3 weeks of open label treatment with...
Pages 8-23 Read Article
ORIGINAL RESEARCH

Methadone Prescribing Patterns at a Single Institution: A Retrospective Study and Clinical Implications

Jamal Hasoon, Amad Qadeer, Grant H Chen, Omar Viswanath, Ivan Urits, Christopher L Robinson
Background Methadone is a long-acting opioid utilized in the management of chronic pain and opioid dependency. Given its unique pharmacokinetics and potential for both therapeutic benefit and risk, understanding prescribing patterns is essential. This study...
Pages 43-54 Read Article
ORIGINAL RESEARCH

Comparison of Stress, Anxiety and Depression in Preclinical and Clinical Dental Students

Yohana Yusra, Indrayadi Gunardi, Wiwiek Poedjiastoeti, Anggraeny Putri Sekar Palupi, Ade Prijanti Dwisaptarini, Jamison Wijaya, Elizabeth Fitriana Sari
Objective To compare factors correlating with stress, anxiety, and depression between dental students (DS) in preclinical (PP) and clinical programs (CP). Method This study involved 165 DS, utilizing the DASS-21, GAD-7, PSS-10, and PHQ-9 assessments....
Pages 55-67 Read Article
ORIGINAL RESEARCH

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation

Valentin Skryabin, Sergei Miroshkin, Anton Masyakin, Sergei Pozdniakov, Valentina Ivanchenko, Valery Shipitsin
Alcohol use disorder (AUD) remains a major contributor to the global burden of disease. Extended-release naltrexone (XR-NTX), a μ-opioid receptor antagonist, is a key pharmacological option for maintaining abstinence, though individual treatment response varies substantially....
Pages 68-78 Read Article
GENERAL PSYCHIATRY

Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression

Ahmed Elmosalamy, Nicola Keeth, Jin Hong Park, Danielle J Gerberi, Susan L McElroy, Mark A Frye, Balwinder Singh
Purpose Individuals with Bipolar II disorder (BD-II) face high rates of depression and have limited FDA-approved treatments, leading to treatment delays and poor functioning. Although not commonly recommended, monoaminergic antidepressants are prescribed to 50% of...
Pages 79-103 Read Article
COMPLICATED CASE HISTORY

Cannabidiol Induced Manic Episode: A Case Report

Anas Ibn Auf, Razan A Almakki, Nora M Alhummayani
Background Cannabidiol (CBD), a non-intoxicating compound derived from Cannabis sativa, has gained widespread popularity for its proposed therapeutic effects in conditions such as anxiety, insomnia, and chronic pain. Unlike tetrahydrocannabinol (THC), CBD is often perceived...
Pages 116-122 Read Article
COMPLICATED CASE HISTORY

Reversible Lacosamide Interference in Electroconvulsive Therapy: A Case Report

Greg Miglis, Greg Noe, Molly Cinderella, Nona Nichols, Sahil Munjal
Ms. M is a 64-year-old female with a psychiatric history of schizoaffective disorder, bipolar type, and malignant catatonia, receiving biweekly maintenance electroconvulsive therapy (ECT). Her medical history includes hypertension, Parkinson’s disease, a reported seizure disorder,...
Pages 123-126 Read Article